Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products.
Cyto-Facto has raised $7.6M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Cyto-Facto's investors include Mizuho Capital, SMBC Venture Capital, Mitsubishi Corporation, MPower Partners, Asahi Kasei.
Cyto-Facto is headquartered in Minamimachi, Japan.
Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products.
Cyto-Facto is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyto-Facto — Funding & Investors." VCBacked, April 22, 2024, https://www.vcbacked.co/company/cyto-facto. Accessed August 14, 2026.
VCBacked. (2024). Cyto-Facto — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cyto-facto
{{cite web |title=Cyto-Facto — Funding & Investors |url=https://www.vcbacked.co/company/cyto-facto |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated